TMCnet News
Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development StrategyBUFFALO, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Daniel Lang, MD, as President of Axis Therapeutics Limited and Senior Director of Corporate Development at Athenex, Inc. Dr. Lang joins Axis and Athenex to lead the operations of the company’s T-cell receptor-engineered T cells (TCR-T) immunotherapy platform for oncology and to assist with corporate development strategy for Athenex. In this new role, Dr. Lang will report to Dr. Johnson Lau, Chief Executive Officer of Athenex and Axis, and will work closely with the management teams of both companies. Dr. Lang has more than 25 years of experience as a physician, scientist and investor. Most recently, he was the Chief Investment Officer of RS Value, an investment franchise of Victory Capital, overseeing the RS Value strategies, as well as an analyst and portfolio manager for healthcare investments since 2009. Prior to RS Value, Dr. Lang was an analyst at Farallon Capital Management, a global multi-strategy hedge fund, responsible for healthcare investments. Dr. Lang started his career as a physician scientist, completing a cardiology fellowship at the University of California, San Francisco. He earned his B.A. in Chemistry from Cornell University and M.D. from Weill Cornell Medical College. “We are delighted to have Daniel join us at this important time,” stated Dr. Johnson Lau, Chairman and CEO of Athenex and CEO of Axis. “With his experience as an executive and successful investor, we look forward to the leadership and insight he will bring to Athenex and Axis as we continue to execute on our mission to deliver innovative products that will improve patient outcomes in oncology.” Dr. Lang commented, “Athenex is a leading biotechnology company with positive Phase III results from two pivotal programs for oral paclitaxel and encequidar and for tirbanibulin ointment. The company is in a unique and enviable position of developing a rich pipeline of products spanning small molecules, biologics, and cell therapies that have the potetial to transform oncology treatment. I am thrilled to join an organization with an innovative culture and a clear mission to improve patients’ lives.” In July 2018, Athenex and Xiangxue Life Sciences (“XLifeSc”) entered into an agreement to establish a new joint venture named Axis Therapeutics Limited, which owns the global (excluding mainland China) rights to the T-cell receptor Affinity Enhanced Specific T-cell (TAEST) technology. XLifeSc retains the mainland China rights. Axis Therapeutics is leading the research, development and commercialization efforts of T-cell receptor-engineered T cells, a form of cancer immunotherapy, in the licensed territories. About Athenex, Inc. Forward-Looking Statements CONTACTS Athenex, Inc.: Jacqueline Li |